(Q42473677)

1 November 2017

title

Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism (English)

1 reference

1 November 2017

1 reference

Mahlon D Johnson

1

1 reference

1 November 2017

Mary O'Connell

series ordinal

2

1 reference

1 November 2017

Webster Pilcher

series ordinal

3

1 reference

1 November 2017

publication date

2 July 2010

1 reference

Journal of Neuro-Oncology

1 November 2017

published in

1 reference

1 November 2017

volume

101

1 reference

1 November 2017

issue

3

1 reference

1 November 2017

page(s)

441-448

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-010-0281-y

1 November 2017

exact match

0 references

cites work

Epidemiology and etiology of intracranial meningiomas: a review

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Meningioma grading: an analysis of histologic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Recurrent spheno-orbital meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

The use of stereotactic radiosurgery in the management of meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

New prospects for management and treatment of inoperable and recurrent skull base meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Targeted drug therapy for meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Antitumour effects of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Bone morphogenetic protein 4 and its receptors are expressed in the leptomeninges and meningiomas and signal via the Smad pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

The expression of survivin and Ki-67 in meningiomas: correlation with grade and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Finding new tricks for old drugs: an efficient route for public-sector drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

Repositioning HIV protease inhibitors as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0281-Y

The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20596751

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20596751

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-010-0281-Y

1 reference

Dimensions Publication ID

1 November 2017

1027802343

0 references

1 reference